#oncology #Australia #Sydney #Kazia Therapeutics #Paxalisib

Kazia Therapeutics Limited Initiates Public Offering to Fund Clinical Advancements

Kazia Therapeutics Limited (NASDAQ: KZIA), an innovative biotechnology firm specializing in cancer therapies, recently disclosed the launch of a tranched registered public offering. This initiative is pivotal in supporting the company’s mission to transform cancer treatment through its advanced oncology portfolio.

Offering Details

The public offering will consist of American Depositary Shares (ADSs), with each share representing five hundred ordinary shares of the company. In addition, it includes pre-funded warrants for select investors. The offering is structured to provide investors with Series A and Series B warrants, each with specific exercise prices and expiration timelines linked to Kazia's data readouts concerning critical breast cancer studies.

Kazia’s offering is being managed by Leerink Partners and Guggenheim Securities as joint bookrunning managers, with BTIG, Needham Company, and Laidlaw Company participating as co-managers. The extent of the offering is contingent on market conditions and comes with no guarantees as to its completion or specific terms.

Funding Usage

Proceeds from this offering are earmarked for the continued clinical development of paxalisib, Kazia's promising investigational drug targeting various cancer forms, including triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer. In addition, the funding will be allocated for working capital and general corporate purposes, ultimately bolstering Kazia’s efforts to bring its innovative treatments to market.

Regulatory Framework

The ADSs and associated warrants are being made available under a previously filed registration statement with the Securities and Exchange Commission (SEC). Investors and interested parties can access a detailed prospectus, which will include all relevant offering terms, through the SEC’s website as well as directly from the managing partners.

About Kazia Therapeutics

Founded and based in Sydney, Australia, Kazia Therapeutics Limited is at the forefront of oncology-focused drug development. The company’s lead asset, paxalisib, is designed to inhibit the PI3K/Akt/mTOR signaling pathway, which plays a crucial role in the proliferation of numerous cancers. Since its inception, paxalisib has been part of over 15 clinical trials, demonstrating promising results in various studies, particularly in glioblastoma, a highly aggressive brain cancer.

Kazia’s commitment to innovative cancer treatments extends beyond paxalisib; the company is also advancing multiple clinical-stage programs, including EVT801, a small molecule inhibitor of VEGFR3. Their forward-looking approach encompasses developing therapies to combat resistance to existing treatments, enhancing the efficacy of immunotherapies, and addressing significant unmet medical needs in oncology.

Forward-Looking Statements

As with any public offering, Kazia Therapeutics cautions potential investors about the inherent risks and uncertainties involved. While management provides optimistic projections regarding clinical milestones and financial outcomes, actual results may vary significantly. Stakeholders are encouraged to review Kazia's filings with the SEC for detailed insights into potential risks and factor considerations.

In summary, Kazia Therapeutics Limited's public offering marks a strategic step toward advancing significant oncology research and innovation. With a robust pipeline and a commitment to addressing some of the most challenging cancer types, Kazia is poised to make notable contributions to the field of cancer therapeutics in the coming years.